Xiaoming Feng

Xiaoming Feng

Auto-generated profile, based on publicly available information

Xiaoming Feng

Division of Biomaterials and Tissue Engineering, National Institutes for Food and Drug Control , Beijing, P.R. China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Tissue Engineering Part A
Verified
Journal Article
Closed access
CWChunren Wang
Chunren Wang
AWAnqi Wang
Anqi Wang
XFXiaoming Feng
Xiaoming Feng
LKLinnan Ke
Linnan Ke
YHYuanli Huang
Yuanli Huang
ZYZhaopeng Yang
Zhaopeng Yang
Tissue engineered medical products (TEMPs) employ state-of-the-art technologies and offer the patients with alternative clinical options for diseases that conventional treatments may fail or be incompetent. However promising, this technology is comparatively new with very limited hands-on experiences with both manufacturing and clinical therapy. Of great significance to products with such complexity and novelty is the establishment of a complete jurisdiction framework and a standardization database so that the safety of the technique in clinical treatment can be ensured. Although different regulatory routes are adopted in different countries, risks are generally considered to be derived from the cellular components within the product, the material scaffolds and potentially from the final products. This article is to provide an insight of the regulatory considerations and the role of China Food and Drug Administration (CFDA) in the supervision of TEMPs.